Zydus Lifesciences: EBITDA growth (+24% YoY*) was led by strong sales growth (+38% QoQ jump in US sales and +13% YoY in EMs; India saw mo...

India’s healthcare sector is poised for growth, with an expected steady 11-12% CAGR over the next five years, led by favourable macroecon...

We have analysed TCS’ annual report and some key highlights include (1) near-term growth uncertainty due to weak discretionary, but mediu...

Mankind Pharma (Mankind) reported 42% YoY EBITDA growth, led by 19% YoY sales growth (India formulation up 11% YoY and exports grew 230% ...

Crompton’s core portfolio (standalone), in line with its Crompton 2.0 strategy, continued to report strong performance as revenue/EBITDA/...

Mahindra & Mahindra: M&M Q4FY24 PAT at INR 21.6bn beat our estimate of INR 17.9bn, aided by better realisation and soft commodity prices....

Colgate Palmolive's 4QFY24 results exceeded consensus estimates, marking the first quarter of positive volume-led growth after eight cons...

Dixon’s mobile division continued to drive overall topline growth as it doubled in revenues both in Q4 and FY24. Post the acquisition of ...

Shree Cement: We maintain our ADD rating on Shree Cement, with an unchanged SOTP target price of INR 28,700/share. Cement volume growth s...

Devyani’s (DIL) 4QFY24 results were below our estimates, as core brands (KFC and PH) disappointed on the SSSG front. Although the India ...

Subscribe for our
newsletter

Reports

__heading__